Ohio State’s cancer hospital names CEO

William Farrar, MD
William Farrar

William Farrar, MD, has been named CEO of The Ohio State University Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

The appointment is pending approval by the university’s board of trustees.

Farrar — a surgical oncologist who has served on the institution’s medical staff since it opened in 1990 — has served as interim leader for nearly 2 years.

Farrar is the Dr. Arthur G. and Mildred C. James – Richard J. Solove chair in surgical oncology; director of Stefanie Spielman Comprehensive Breast Center; and member of the molecular carcinogenesis and chemoprevention research program at The Ohio State University Comprehensive Cancer Center. He directed the division of surgical oncology for 28 years and served as director of medical affairs for 22 years.

“We’ve built a tremendous cancer hospital and research enterprise,” Farrar said in a press release. “I am honored to continue to do my part to help lead our clinical enterprise as we embrace a very hopeful new area of genomic-driven care and immuno-oncology approaches that allow us to offer personalized, more effective treatment options to our patients.”

William Farrar, MD
William Farrar

William Farrar, MD, has been named CEO of The Ohio State University Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

The appointment is pending approval by the university’s board of trustees.

Farrar — a surgical oncologist who has served on the institution’s medical staff since it opened in 1990 — has served as interim leader for nearly 2 years.

Farrar is the Dr. Arthur G. and Mildred C. James – Richard J. Solove chair in surgical oncology; director of Stefanie Spielman Comprehensive Breast Center; and member of the molecular carcinogenesis and chemoprevention research program at The Ohio State University Comprehensive Cancer Center. He directed the division of surgical oncology for 28 years and served as director of medical affairs for 22 years.

“We’ve built a tremendous cancer hospital and research enterprise,” Farrar said in a press release. “I am honored to continue to do my part to help lead our clinical enterprise as we embrace a very hopeful new area of genomic-driven care and immuno-oncology approaches that allow us to offer personalized, more effective treatment options to our patients.”